References
1. Blenkinsopp A, Wilkie P, Wang M, Routledge PA. Patient reporting of
suspected adverse drug reactions: a review of published literature and
international experience. Br J Clin Pharmacol 2007;63:148-156.
2. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions
in hospitalized patients: A meta-analysis of prospective studies. JAMA
1998;279:1200-1205.
3. Bielinski SJ, Olson JE, Pathak J, et al. Preemptive genotyping for
personalized medicine: design of the right drug, right dose, right time
– using genomic data to individualize treatment protocol. Mayo Clin
Proc 2014;89:25-33.
4. Rasmussen-Torvik LJ, Stallings SC, Gordon AS, et al. Design and
anticipated outcomes of the eMERGE-PGx project: A multi-center pilot for
pre-emptive pharmacogenomics in electronic health record systems. Clin
Pharmacol Ther 2014;96:482-489.
5. Dolgin E. Preemptive genotyping trialed to prevent adverse drug
reactions. Nat Med 2011;17:1323.
6. Driest SV, Shi Y, Bowton EA, et al. Clinically actionable genotypes
among 10,000 patients with preemptive pharmacogenomic testing. Clin
Pharmacol Ther 2014;95:423-431.
7. Saito Y, Stamp LK, Caudle KE, et al. Clinical pharmacogenetics
implementation consortium (CPIC) guidelines for human leukocyte antigen
B (HLA-B) genotype and allopurinol dosing: 2015 update. Clin Pharmacol
Ther 2016;99:36-37.
8. Kim GJ, Lee SY, Park JH, Ryu BY, Kim JH. Role of preemptive
genotyping in preventing serious adverse drug events in South Korean
patients. Drug Saf 2017;40:65-80.
9. Fan WL, Shiao MS, Hui RCY, et al. HLA association with drug-induced
adverse reactions. J Immunol Res 2017;2017:3186328.
10. Zhou Y, Krebs K, Milani L, Lauschke VM. Global frequencies of
clinically important HLA alleles and their implications for the
cost-effectiveness of preemptive pharmacogenetic testing. Clin Pharmacol
Ther 2020;e-pub ahead of print June 14 2020; doi:10.1002/cpt.1944.
11. Lee KH, Kim HJ, Kim Y-J, Kim JH, Song EY. Extracting structured
genotype information from free-text HLA reports using a rule-based
approach. J Korean Med Sci 2020;35:e78.
12. Relling MV, Klein T. CPIC: clinical pharmacogenetics implementation
consortium of the pharmacogenomics research network. Clin Pharmacol
Ther 2011;89:464-467.
13. Ruxton GD, Neuhäuser M. Review of alternative approaches to
calculation of a confidence interval for the odds ratio of a 2× 2
contingency table. Methods Ecol Evol 2013;4:9-13.
14. R Core Team. R: A Language and Environment for Statistical
Computing. R Foundation for Statistical Computing; 2018.https://www.R-project.org/Accessed 8. 11. 2020.
15. Park Y-T, Kim YS, Yi B-K, Kim SM. Clinical decision support
functions and digitalization of clinical documents of electronic medical
record systems. Health Infor Res 2019;25:115-123.
16. Gough SCL, Simmonds MJ. The HLA Region and autoimmune disease:
Associations and mechanisms of action. Curr Genomics 2007;8:453-465.
17. Blackwell JM, Jamieson SE, Burgner D. HLA and infectious diseases.
Clin Microbiol Rev 2009;22:370-385.
18. Mockenhaupt M. Epidemiology of cutaneous adverse drug reactions.
Allergol Sel 2017;1:96-108.
19. Hung S-I, Chung W-H, Liou L-B, et al. HLA-B*5801 allele as a genetic
marker for severe cutaneous adverse reactions caused by allopurinol.
Proc Natl Acad Sci U S A 2005;102:4134-4139.
20. Kang H-R, Jee YK, Kim Y-S, et al. Positive and negative associations
of HLA class I alleles with allopurinol-induced SCARs in Koreans.
Pharmacogenet Genomics 2011;21:303-307.
21. Chung W-H, Hung S-I, Hong H-S, et al. Medical genetics: a marker for
Stevens-Johnson syndrome. Nature 2004;428:486.
22. Jung J-W, Kim J-Y, Park I-W, Choi B-W, Kang H-R. Genetic markers of
severe cutaneous adverse reactions. Korean J Intern Med 2018;33:867-875.
23. Kim S-H, Lee KW, Song W-J, et al. Adverse Drug Reaction Research
Group in Korea. Carbamazepine-induced severe cutaneous adverse reactions
and HLA genotypes in Koreans. Epilepsy Res 2011;97:190-197.
24. Tangamornsuksan W, Scholfield N, Lohitnavy M. Association between
HLA genotypes and oxcarbazepine-induced cutaneous adverse drug
reactions: a systematic review and meta-analysis. J Pharm Pharmaceutical
Sciences 2018;21:1-18.
25. Mushiroda T, Takahashi Y, Onuma T, et al. Association of HLA-A*31:01
screening with the incidence of carbamazepine-induced cutaneous adverse
reactions in a Japanese population. JAMA Neurol 2018;75:842-849.
26. Lorenz M, Wozel G, Schmitt J. Hypersensitivity reactions to dapsone:
a systematic review. Acta Derm Venereol 2012;92:194-199.
27. In JW, Roh EY, Oh S, Shin S, Park KU, Song EY. Allele and haplotype
frequencies of human leukocyte antigen-A, -B, -C, -DRB1, and -DQB1 from
sequence-based DNA typing data in Koreans. Ann Lab Med 2015;35:429-435.
28. Lee KW, Oh DH, Lee C, Yang SY. Allelic and haplotypic diversity of
HLA-A, -B, -C, -DRB1, and -DQB1 genes in the Korean population. Tissue
Antigens 2005;65:437-447.
29. Green RC, Berg JS, Grody WW, et al. ACMG Recommendations for
Reporting of Incidental Findings in Clinical Exome and Genome
Sequencing. Genet Med Off J Am Coll Med Genet 2013;15:565-574.
30. Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics
knowledge for personalized medicine. Clin Pharmacol Ther
2012;92:414-417.
31. Gonzalez-Galarza FF, McCabe A, Dos Santos EJM, et al. Allele
frequency net database. In HLA Typing. Humana Press, New York, NY.
2018:49-62
32. Small CB, Margolis DA, Shaefer MS, Ross LL. HLA-B*57:01 allele
prevalence in HIV-infected North American subjects and the impact of
allele testing on the incidence of abacavir-associated hypersensitivity
reaction in HLA-B*57:01-negative subjects. BMC Infect Dis 2017;17:256.
33. Ko TM, Tsai CY, Chen SY, et al. Use of HLA-B*58:01 genotyping to
prevent allopurinol induced severe cutaneous adverse reactions in
Taiwan: national prospective cohort study. BMJ 2015;351:h4848.
34. Niihara H, Kaneko S, Ito T, et al. HLA-B*58:01 strongly associates
with allopurinol-induced adverse drug reactions in a Japanese sample
population. J Dermatol Sci 2013;71:150-152.
35. Jung JW, Song WJ, Kim YS, et al. HLA-B58 can help the clinical
decision on starting allopurinol in patients with chronic renal
insufficiency. Nephrol Dial Transplant. 2011;26:3567–72.
36. Ferrell PB, McLeod HL. Carbamazepine, HLA-B*1502 and risk of
Stevens–Johnson syndrome and toxic epidermal necrolysis: US FDA
recommendations. Pharmacogenomics. 2008;9:1543–6.
37. Yuliwulandari R, Kristin E, Prayuni K, Sachrowardi Q, Suyatna FD,
Menaldi SL, et al. Association of the HLA-B alleles with
carbamazepine-induced Stevens–Johnson syndrome/toxic epidermal
necrolysis in the Javanese and Sundanese population of Indonesia: the
important role of the HLA-B75 serotype. Pharmacogenomics.
2017;18:1643-1648.
38. Sun D, Yu C-H, Liu Z-S, et al. Association of HLA-B*1502 and *1511
allele with antiepileptic drug-induced Stevens-Johnson syndrome in
central China. J Huazhong Univ Sci Technol Med Sci 2014;34:146-150.
39. Kaniwa N, Saito Y, Aihara M, et al. HLA-B*1511 is a risk factor for
carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal
necrolysis in Japanese patients. Epilepsia 2010;51:2461-2465.
40. Kim H, Chadwick L, Alzaidi Y, Picker J, Poduri A, Manzi S.
HLA-A*31:01 and oxcarbazepine-induced DRESS in a patient with seizures
and complete DCX deletion. Pediatrics 2018;141:S434-S438.
41. Liu Y, Yu Y, Nie X, Zhao L, Wang X. Association between HLA-Bn*15:02
and oxcarbazepine-induced cutaneous adverse reaction: a meta-analysis.
Pharmacogenomics 2018;19:5475
42. Chen WT, Wang CW, Lu CW, Chen CB, Lee HE, Hung SI, et al. The
function of HLA-B*13:01 involved in the pathomechanism of
dapsone-induced severe cutaneous adverse reactions. J Invest Dermatol.
2018;138:1546–54.
43. Tangamornsuksan W, Lohitnavy M. Association between HLA-B*1301 and
dapsone-induced cutaneous adverse drug reactions: A systematic review
and meta-analysis. JAMA Dermatol 2018;154:441-446.
44. Kim SH, Kim M, Lee KW, et al. HLA-B*5901 is strongly associated with
methazolamide-induced Stevens–Johnson syndrome/toxic epidermal
necrolysis. Pharmacogenomics 2010;11:879-884.
45. Tangamornsuksan W, Lohitnavy M. Association between HLA-B*5901 and
methazolamide-induced Stevens-Johnson syndrome/toxic epidermal
necrolysis: a systematic review and meta-analysis. Pharmacogenomics J
2019;19:286-294.
46. Xu Y, Wu M, Sheng F, Sun Q. Methazolamide-induced toxic epidermal
necrolysis in a Chinese woman with HLA-B5901. Indian J Ophthalmol
2015;63:623-624.
47. Konvinse KC, Trubiano JA, Pavlos R, et al. HLA-A*32:01 is strongly
associated with vancomycin-induced drug reaction with eosinophilia and
systemic symptoms. J Allergy Clin Immunol 2019;144:183-192